Global Bacterial Conjunctivitis Drugs Market is segmented By Disease Type (Acute Bacterial Conjunctivitis, Chronic Bacterial Conjunctivitis), By Drug Type (Fluoroquinolones, Ciprofloxacin, Ofloxacin, Levofloxacin, Moxifloxacin, Gatifloxacin, Besifloxacin, Macrolides), By Route of Administration (Topical, Oral, Intravitreal), By End User (Hospitals Pharmacy, Retail Pharmacy, Other), By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa)– Share, Size, Outlook, and Opportunity Analysis, 2024-2031
Report Overview
The Global Bacterial Conjunctivitis Drugs Market is expected to grow at a CAGR of 2.50% during the forecast period 2024-2031.
Bacterial conjunctivitis is a highly contagious eye condition where the conjunctiva is infected. Staphylococci, streptococci, gonococci, and Chlamydia are a few of the causative agents of bacterial conjunctivitis. In addition, pathogenic bacteria such as Chlamydia trachomatis and Neisseria gonorrhea cause severe bacterial conjunctivitis.
Market Summary
|
Metrics |
Details |
|
Market CAGR |
2.50% |
|
Segments Covered |
By Disease Type, By Drug Type, By Route of Administration, By End User and By Region |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
|
Fastest Growing Region |
Asia Pacific |
|
Largest Market Share |
North America |
For More Insights Request Free Sample
Market Dynamics
The rise in ophthalmic bacterial infections is increasing the demand for antibacterial drugs encourages manufacturers to develop herbal products for bacterial conjunctivitis treatment to earn a profit by fueling the global bacterial conjunctivitis drug market.
Rising incidences of bacterial conjunctivitis and availability of generic drugs to fuel the market growth
The spread of ophthalmic bacterial infection raised the demand for antibacterial medicines for its treatment. For instance, according to the American Academy of Optometry, bacterial conjunctivitis is common worldwide. The estimated incidence of bacterial conjunctivitis in the United States is 135 cases per 10,000 annually, constituting approximately 1% of all primary care consultations. Additionally, there are approximately 5.2 million cases of infectious conjunctivitis in Europe each year.
Certain drugs in the market are patented, and their patents are about to expire; this, in turn, is expected to increase the market for generic drugs, which are of less price. Mozza, vigamox, besivance, and zymaxid are some of the most successful patented drugs about to expire. After patent expiry, these drugs lose their exclusivity, which leads to an increase in the use of generic drugs. In addition, the development of multi-drug resistant variants is expected to fuel the growth of the bacterial conjunctivitis drug market. The unnecessary use of antibiotics causes the disease-causing bacteria to evolve themselves and become resistant to drugs chemically. This factor, in turn, may lead to the prescription of strong medication, which includes corticosteroids and a high dose of antibiotics. This factor will drive the market growth in the forecast period.
Devlopment of new drugs of bacterial conjunctivitis is driving the market growth
The rising occurrence of bacterial conjunctivitis demands safe and efficient drugs, which leads to the development of new drugs, such as vancomycin ophthalmic ointment, that are in the clinical trial pipeline, and few are pending approval. The preference toward herbal medicine from pharmacological therapy is supposed to create new market opportunities. Moreover, herbal formulation-based drugs are widely accepted, leading to the development and investment in herbal products for the treatment of bacterial conjunctivitis. Therefore, the scenario mentioned above is expected to support the growth of the bacterial conjunctivitis drugs market over the forecast period.
Scarcity of novel compounds for clinical examination is likely to hamper market growth
However, the market is required to face a patent cliff in the upcoming years. As a result, the availability of specific cost-effective medicines is likely to hamper the market growth extensively. In addition, the scarcity of novel compounds available for preclinical and clinical examination is affecting the growth of the market.
The absence of investigations regarding approval of drugs and bacterial conjunctivitis in the pipeline affects the market for bacterial conjunctivitis in the U.S. The increase in drug expiry is pointing to doctors prescribing various generic medications that are affordable, thus hindering the market growth. In addition, optometrists and ophthalmologists are mainly prescribing antibiotics as creams and eye drops which is affecting the market growth.
COVID-19 Impact Analysis on Bacterial Conjunctivitis Drugs Market
COVID 19 can cause bacterial conjunctivitis when the virus infects a tissue called the conjunctiva, covering the white part of the eye or the inside eyelids. Based on data so far by CDC, doctors believe that 1%-3% of people with COVID-19 will get conjunctivitis. Thus the growing prevalence of COVID 19 cases across the world has increased the cases of bacterial conjunctivitis. This factor will drive the growth of the market during the pandemic.
Market Segmentation Analysis
Acute bacterial conjunctivitis segment is expected to grow at the fastest CAGR during the forecast period (2024-2031)
Acute bacterial conjunctivitis is an infection of the eye in which single or both eyes convert red with associated distress. The condition is not usually complex and, in most instances, clears up without medication. People with acute conjunctivitis are usually given antibiotics, usually in eye drops or cream, to speed recovery. However, the advantages of antibiotics for the therapy of acute bacterial conjunctivitis have been investigated. Evidence from clinical trials in GP methods suggests that antibiotic drops may be less effective since these patients tend to have a limited severe form of conjunctivitis than patients transferred to a hospital eye clinic.
The expected incidence of acute bacterial conjunctivitis in the U.S. is 135 cases per 10,000 population annually, creating approximately 1% of all primary care consultations. These factors are driving the segment growth in the forecast period.
Fluoroquinolones segment are expected to dominate the Bacterial conjunctivitis drugs market, by drug type, during the forecast period
The fluoroquinolones are bactericidal and have a broad spectrum of activity against Gram-positive and Gram-negative pathogens that cause bacterial conjunctivitis. Fluoroquinolones bacterial conjunctivitis antibiotics inhibit DNA gyrase and topoisomerase IV activity, preventing DNA replication in susceptible organisms. Fluoroquinolones such as moxifloxacin, gatifloxacin, and besifloxacin, which exhibit the most balanced inhibitory activity, and have a structural modification that acts as a balancing binding for DNA gyrase and topoisomerase IV, which helps them exhibit improved activity against common Gram-positive pathogens, including strains of Staphylococci and Streptococci that are resistant to other antibiotics.
Fluoroquinolones ophthalmic solutions are usually less toxic than the older antibiotics, making them more tolerable. Among fluoroquinolones preparations, drugs such as ciprofloxacin, ofloxacin, levofloxacin, and gatifloxacin are administered more frequently than moxifloxacin and besifloxacin.
The FDA approved Fluoroquinolones drugs primarily used for bacterial conjunctivitis, which might boost the global bacterial conjunctivitis drug market.
Market Geographical Share
North America region holds the largest market share in the Global Bacterial Conjunctivitis Drugs Market
North America is dominating the market due to the increasing prevalence of bacterial conjunctivitis. For instance, according to the American Academy of Ophthalmology, bacterial conjunctivitis affects 6 million people in the United States each year. It is a significant driver of emergency room visits for ocular problems. The pipeline drug for bacterial conjunctivitis is a crucial factor boosting the market.
For instance, in April 2017, Shire introduced the initiation of Phase 3 clinical trial for SHP640 in the U.S, a combination of broad-spectrum antiseptic and corticosteroid in development for the treatment of infectious disorders conjunctivitis in adults and adolescents. SHP640 is being evaluated for adenoviral and bacterial conjunctivitis, which are highly infectious diseases of the ocular surface.
However, it has been noted that although the percentage rate of bacterial conjunctivitis is moderate in the U.S., the risk of morbidity is less, due to which the new product pipeline for bacterial conjunctivitis is weak/dry. Currently, only a few novel compounds are under research in both preclinical and clinical settings to treat bacterial conjunctivitis.
Market Companies and Competitive Landscape
The bacterial conjunctivitis drugs market is moderately competitive with the presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Pfizer Inc., Novartis AG, Hoffmann-La Roche, Bayer Healthcare, Valeant Pharmaceutical International Inc., Akorn Inc., Santen Pharmaceutical Co. Ltd., Allergan Plc, Otsuka Pharmaceutical Co., Ltd.,Shanghai MicroPort Medical (Group) Co.,Ltd., Zhaoke Ophthalmology Pharmaceuticals Limited among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the bacterial conjunctivitis drugs market globally.
Market Key Companies to Watch
Okogen
Overview: Okogen, founded in 2015, is a clinical-stage ophthalmic specialty biotechnology company. They are the developer of ophthalmic anti-infective designed to treat unmet needs in ophthalmic infectious diseases. The company's anti-invectives are focused on infectious ocular diseases where treatments are either not available or unsatisfactory and provide an opportunity to address adenoviral infections of the eye as well as other classes of viruses that are active in the ocular space, including herpes simplex virus, varicella-zoster virus and picornavirus, enabling adults and children to reduce suffering, improve quality of life and preserve vision..
Product Portfolio: The Company offers focused on developing innovative therapies to treat adenoviral conjunctivitis. The company lead product candidate, OKG-0502, is being developed to treat adenoviral conjunctivitis (also known as pink eye), a viral infection that affects approximately 30 million people worldwide each year and for which there are no approved therapies.
Key Development: In January 2019, Okogen, a biotech company developing ophthalmic therapeutics, has introduced a Phase II clinical trial for patients with conjunctivitis across Australia. The Phase II clinical trial RUBY will take place at seven clinical sites in Sydney, Melbourne, Albury, Adelaide, Perth and Hobart. The RUBY trial is a phase II, multi-site, randomized, placebo-controlled, double-blinded clinical trial, will evaluate multiple doses of OKG-0301.
